Comparative Pharmacology
Head-to-head clinical analysis: SULF 10 versus SULFABID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULF 10 versus SULFABID.
SULF-10 vs SULFABID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sulfacetamide inhibits bacterial dihydropteroate synthase, blocking folate synthesis and thereby nucleic acid production.
Sulfonamide antibiotic that competitively inhibits dihydropteroate synthase, blocking para-aminobenzoic acid (PABA) incorporation into dihydrofolate and thereby inhibiting bacterial folate synthesis.
One to two drops of SULF-10 ophthalmic solution (10% sulfacetamide sodium) instilled into the affected eye(s) every 2-3 hours initially, then decreasing frequency as infection resolves, up to 5-6 times daily.
500 mg orally every 12 hours for 10-14 days.
None Documented
None Documented
Terminal elimination half-life is 7-12 hours in adults with normal renal function; prolonged in renal impairment
Terminal elimination half-life: 8-12 hours in adults with normal renal function; prolonged to 20-50 hours in renal impairment (CrCl <30 mL/min), requiring dose adjustment.
Renal excretion of unchanged drug and acetylated metabolites: ~85-90%; biliary/fecal: ~10-15%
Renal: 80-90% unchanged via glomerular filtration and tubular secretion. Biliary: 5-10% as metabolites. Fecal: <5%.
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)